Hcv genotype 3 replicons
AssigneeGilead Sciences, Inc.
InventorsWilliam E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Mei Yu, Amoreena Corsa
Life of this patent
Estimating the term…
Abstract
Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.
Claims45
A genotype 3 hepatitis C viral (HCV) RNA construct that is capable of replication in a eukaryotic cell, wherein the RNA sequence comprises a 5′NTR, an internal ribosome entry site (IRES), sequences encoding one or more of NS3, NS4A, NS4B, NS5A or NS5B, and a 3′NTR.
An NS3 protein of HCV genotype 3 that comprises a serine at residue 607.
An NS3 protein of HCV genotype 3 that comprises a leucine at residue 89.
An isolated cell comprising a genotype 3 hepatitis C viral (HCV) RNA that replicates in the cell.
A method of improving the capability of a genotype 3 HCV viral RNA to replicate in a eukaryotic cell, comprising substituting residue 607 of NS3 with a serine.
A method of improving the capability of a genotype 3 HCV viral RNA to replicate in a eukaryotic cell, comprising substituting residue 89 of NS3 with a leucine.
Dependencies are inferred from the claim text.